EVOLOCUMAB PHARMACOKINETICS AND ITS EFFECTS ON LDL-C AND PCSK9 LOWERING IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT.

被引：0
|
作者：
Emery, M. G. [1 ]
Gibbs, J. P. [1 ]
Slatter, J. G. [2 ]
Hamilton, L. [3 ]
Wasserman, S. M. [1 ]
Geller, M. [1 ]
Dias, C. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Amgen Inc, Seattle, WA USA
[3] Amgen Ltd, Uxbridge, Middx, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-034
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [1] Lowering LDL-C with alirocumab, an investigational PCSK9 inhibitor
    Edelberg, Jay
    CLINICAL LIPIDOLOGY, 2014, 9 (06) : 603 - 606
  • [2] THERAPEUTIC LDL-C LOWERING WITH PCSK9 DIRECTED OLIGONUCLEOTIDE THERAPY (INCLISIRAN) IN A PATIENT WITH FAMILIAL HYPERLIPIDEMIA (FH) REFRACTORY TO PCSK-9 MONOCLONAL ANTIBODY (EVOLOCUMAB)
    Skove, Stephanie
    Anderson, Jeffrey L.
    Le, Viet T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2474 - 2474
  • [3] Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering
    Rodriguez, Fatima
    Harrington, Robert A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (19): : 1967 - 1968
  • [4] Lubeluzole pharmacokinetics in subjects with mild, moderate and severe renal impairment.
    Burstein, AH
    Lee, PID
    Gajjar, D
    Zhou, H
    Soo, Y
    Pesco-Koplowitz, L
    Hantson, L
    Woestenborghs, R
    Young, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 189 - 189
  • [5] FTY720 pharmacokinetics in mild to moderate hepatic impairment.
    Kovarik, JM
    Schmouder, RL
    Serra, D
    Wang, Y
    Lasseter, K
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 473 - 473
  • [6] Predictors of Residual Plaque Progression Despite Achieving Low Levels of LDL-C With the PCSK9 Inhibitor, Evolocumab
    Honda, Satoshi
    Puri, Rishi
    Anderson, Todd
    Kastelein, John J.
    Brennan, Danielle M.
    Kassahun, Helina
    Somaratne, Ransi
    Wasserman, Scott M.
    Nissen, Steven E.
    Nicholls, Stephen J.
    CIRCULATION, 2017, 136
  • [7] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S88 - S88
  • [9] Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
    Roth, Eli M.
    Kastelein, John Jp
    Cannon, Christopher P.
    Farnier, Michel
    McKenney, James M.
    DiCioccio, A. Thomas
    Brunet, Aurelie
    Manvelian, Garen
    Sasiela, William J.
    Baccara-Dinet, Marie T.
    Zhao, Jian
    Robinson, Jennifer G.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (05) : 707 - 719
  • [10] Is sEHi lowering LDL-C by reducing expression of PCSK9 through SREBP2 pathway?
    Liu, Qiong
    Guo, Yuan
    Gui, Ya-jun
    Liao, Cai-xiu
    Xu, Dan-yan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 207 : 361 - 362
12345